SCH772984作為ERK抑制劑在巨噬細胞表型轉(zhuǎn)換機制研究中的應用
瀏覽次數(shù):23 發(fā)布日期:2026-3-20
來源:本站 僅供參考,謝絕轉(zhuǎn)載,否則責任自負
SCH772984(AbMole,M2084)是一種特異性ERK1/2抑制劑,在多項基礎(chǔ)研究中被廣泛用于探究ERK信號通路的功能及其調(diào)控機制。在細胞實驗中,SCH772984(CAS No.:942183-80-4)被用于RAW264.7巨噬細胞系,通過預孵育,觀察其對表型轉(zhuǎn)換的影響[1];SCH772984在HT-29結(jié)腸癌細胞、NCI-H1373肺癌細胞及MDA-MB-231乳腺癌細胞等多種腫瘤細胞系中,被用于驗證ERK通路在細胞增殖、凋亡及遷移中的作用。此外,在鐵死亡研究中,SCH772984與SP1 siRNA共同使用可顯著降低
Fer-1(Ferrostatin-1,鐵抑素-1)誘導的神經(jīng)元和星形膠質(zhì)細胞中SP1和GPX4蛋白水平的升高,并逆轉(zhuǎn)GFAP和Iba1的下調(diào),提示其在調(diào)控氧化應激相關(guān)通路中的作用[2]。
在動物實驗中,通過腹腔注射SCH772984處理脾切除的小鼠,觀察到SCH772984可調(diào)控肝臟浸潤型巨噬細胞的表型轉(zhuǎn)換[1]。
SCH772984(AbMole,M2084)在靜脈移植(VGA)大鼠模型中通過阻斷EphB4的表達,抑制EphB4轉(zhuǎn)基因大鼠的血管移植物硬化(VGS)過程[3]。在神經(jīng)相關(guān)研究中,SCH772984經(jīng)鞘內(nèi)注射可抑制小鼠部分坐骨神經(jīng)結(jié)扎模型中L3背根神經(jīng)節(jié)(DRG)中ERK磷酸化及腫瘤壞死因子α(TNFα)上調(diào),并緩解機械性痛覺超敏。在膿毒癥相關(guān)研究中(小鼠模型),SCH772984被證實具有改善小鼠膿毒癥的潛力[4]。
范例詳解
Mol Cancer. 2022 Mar 18;21(1):77
圖1. holesterol promotes EGFR-TKIs resistance in NSCLC by inducing EGFR/Src/Erk/SP1 signaling-mediated ERRα re-expression
參考文獻及鳴謝
[1] Zheng, Z. Wang, H. Li, L. et al. Splenectomy enhances the Ly6C(low) phenotype in hepatic macrophages by activating the ERK1/2 pathway during liver fibrosis. International immunopharmacology 2020, 86, 106762.
[2] Liu, S. Chen, F. Han, J. et al. Ferrostatin-1 improves neurological impairment induced by ischemia/reperfusion injury in the spinal cord through ERK1/2/SP1/GPX4. Experimental neurology 2024, 373, 114659.
[3] Guo, Y.; Zhu, F. Zhang, X. et al. Extracellular signal-regulated kinase inhibition prevents venous adaptive remodeling via regulation of Eph-B4. Vascular 2022, 30 (1), 120-129.
[4] Kopczynski, M. Rumienczyk, I. Kulecka, M. et al. Selective Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) Inhibition by the SCH772984 Compound Attenuates In Vitro and In Vivo Inflammatory Responses and Prolongs Survival in Murine Sepsis Models. International journal of molecular sciences 2021, 22 (19).